Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Antibody
- Drug Discovery
- Test/Monitoring
- Diagnostic
- Cancer
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 368393
Affinity reagents are fragments of monoclonal antibodies that specifically bind to target proteins and are useful in life science research, diagnostic tests and as therapeutics.
IPSCIO Record ID: 227238
Licensor hereby grants to Licensee, a Japanese corporation, and the Majority-Owned Affiliates of Licensee, solely as needed to exercise the rights that may be granted, a paid-up, non-exclusive license and/or sublicense of its rights, as the case may be, under the Licensed Technology, without the right to grant further sublicenses, to (i) Breed the XenoMouse Animals included solely for use in the Research Field in connection with activities described in subsections (ii) and (iii) of this Section 2.1.1, (ii) immunize such XenoMouse Animals solely with those Antigens that are Permitted Antigens at the time of immunization and (iii) use the Research Program Materials and Information solely for conducting research and development work within the scope of the Research Field.
Licensor hereby grants to Licensee, and the Majority-Owned Affiliates of Licensee solely as needed to practice the rights that may be granted in accordance with this agreement, a paid-up, non-exclusive license and/or sublicense, as the case may be, of its rights in the Licensor Materials and Information and all intellectual property rights Controlled by Licensor related thereto that are not licensed to Licensee pursuant to the license in subsection (a) above, solely to the extent that the Licensor Materials and Information are necessary or useful to Licensees practice of the license granted in subsection (a) above.
Option to enter into Product License Agreement
Licensor hereby grants to Japanese Licensee an exclusive option (an 'Option') to enter into a Product License Agreement with respect to those Permitted Antigens which have been designated as Product Antigens, as further described. Each calendar year during the term of this Agreement, Licensee may obtain up to Two (2) such Options with respect to Product Antigens, pursuant to the procedures set forth.
Product shall mean (i) with regard to the Option Agreement, any composition which incorporates or is derived from (a) an Antibody that binds to a Product Antigen or (b) Genetic Material encoding such an Antibody, wherein in respect of each Product, said Genetic Material does not encode multiple Antibodies; and (ii) with regard to a Product License Agreement, any composition which incorporates or is derived from (a) an Antibody that binds to the Product Antigen (as defined in such Product License Agreement) or (b) Genetic Material encoding such an Antibody wherein, in respect of each Product, said Genetic Material does not encode multiple Antibodies.
Product Antigen shall mean (i) with regard to the Option Agreement, a Permitted Antigen as to which Licensee has obtained an Option, as further described in the Option Agreement; and (ii) with regard to a Product License Agreement, the Antigen described in the Product License Agreement.
Xenomouse Animals shall mean transgenic mice which are Controlled by Licensor and which contain unrearranged human immunoglobulin genes that are capable of producing human antibodies when immunized with an antigen.
XenoMouseâ„¢ is a leading technology for generating fully human antibody drugs useful in treating a wide range of diseases.
XenoMouseâ„¢ is a technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy.
Research Field shall mean the immunization of XenoMouse Animals with Permitted Antigens, the use of materials derived or generated in whole or in part from such XenoMouse Animals that are so immunized, and the use of the XenoMouse Animals themselves, solely for the creation, identification, analysis, manufacture, research, and preclinical development of Products in the Field. For purposes of clarification, it is understood that 'immunization' of XenoMouse Animals with a Permitted Antigen includes the immunization of XenoMouse Animals with any formulation or construction of a Permitted Antigen, regardless of the three dimensional configuration of such Permitted Antigen, including, but not limited to, cell lines expressing such Permitted Antigen on their cell surface and chimeric molecules containing such Permitted Antigen; provided, however, that any research, development or use of Antibodies that bind to an excluded Antigen (other than to determine whether they bind to a Permitted Antigen) shall be outside of the scope of the licenses granted under the Option Agreement.
IPSCIO Record ID: 332228
(a) an Initial License Allocation of up to (31) Product Licenses for Therapeutic Antibody Products and/or Diagnostic Antibody Products shall be available from the Commencement Date;
(b) an Additional License Allocation of up to (75) Product Licenses for Therapeutic Antibody Products and Diagnostic Antibody Products shall be available from the Commencement Date;
(c) (35) Diagnostic Collaboration Licenses for Diagnostic Antibody Products shall be available from the Commencement Date; and
(d) (30) Additional Diagnostic Licenses for Diagnostic Antibody Products shall be available
from the Commencement Date.
Licensor grants the option for Licensee to obtain the (20) Product Licenses for both Therapeutic Antibody Products and Diagnostic Antibody Products, which may be exercised by Licensee only on a cumulative basis in accordance with the following schedule
(a) seven (7) Product Licenses on or before 31 December 2003;
(b) four (4) additional Product Licenses on or before 31 December 2004;
(c) three (3) additional Product Licenses on or before 31 December 2005;
(d) six ( 6) additional Product Licenses on or before 31 December 2006.
In addition to the options for Product Licenses granted, Licensor grants the option for a total of an additional seventy five (75) Product Licenses for both Diagnostic Antibody Products and Therapeutic Antibody Products to be granted to Licensee; provided that if any option for a Product License has not been exercised and granted to Licensee on or before 31 December 2017, then the option for such Product License will lapse irrevocably.
In addition to the options for Product Licenses granted, Licensor grants to the option for a total of an additional thirty-five (35) Product Licenses for Diagnostic Antibody Products developed by Licensee under the Specified Diagnostic Agreements (the Diagnostic Collaboration Licenses); provided that if any option for a Diagnostic Collaboration License has not been exercised by Licensee on or before 31 December 2017, then the option for such Product License will lapse irrevocably.
In addition to the options for Product Licenses granted, Licensor grants to the option for a total of an additional thirty (30), Product Licenses for Diagnostic Antibody Products (the Additional Diagnostic Licenses); provided that if any option for an Additional Diagnostic Licenses has not been exercised by Licensee on or before 31 December 2017, then the option for such Product Licenses will lapse irrevocably.
Prior to the commencement of human trials for a Product, and provided that Licensee obtains a Product License for such Product prior to commencing human trials for such Product, Licensor grants, a non-exclusive, royalty free license in the Territory during the term of this Agreement to use the Licensor Antibody Phage Display Patents and Know-How for the purposes of carrying out research and development activities in relation to identifying Licensor Licensable Antibodies or potential Products.
For the Grant of Product License by Licensor, Licensor agrees grants a non-exclusive, license, with the right to sublicense, under the Licensor Antibody Phage Display Patents and Licensor Know-How to Exploit Products against such Nominated Target in the Territory.
For the Grant of Other Licenses, Licensor grants with effect from 3 January 2003 to Licensee a non-exclusive license in the Territory, with the right to sublicense, under the Licensor Antibody Phage Display Patents and Know-How for any purpose not already covered by the provisions of this Agreement (Other Purposes) including to Exploit any product, other than a Therapeutic Antibody Product, Diagnostic Antibody Product
or Research Product, whose development, manufacture, use or sale would, absent the license hereunder, infringe Valid Claims of the Licensor Antibody Phage Display Patents or utilize the Licensor Know-How (Other Product).
This agreement includes an exclusive option grant from Licensee to Licensor.
Product means a Diagnostic Antibody Product or a Therapeutic Antibody Product.
Licensed Product means any product intended for sale to an End User as a human or non-human therapeutic or in vitro diagnostic or research reagent ( and in the case of a diagnostic or research reagent contains one or more antibodies as a binding moiety) that prior to or after December 31, 1997 (the effective date of the Original Agreements) is discovered, made or developed, whether by Licensor, its Affiliates or any Commercial Party, using a Licensed Intermediate or a method covered in whole or in part by the Licensee Patent Rights.
IPSCIO Record ID: 369249
Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the HuMAb Technology and the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import
— Licensed Royalty-Bearing Products solely in the Antibody Targeting Technology Field, and,
— Anti-Mannose Products.
For Hybridoma Cell Lines; Research License, Licensor grants an exclusive, worldwide license, with the right to sublicense, under the HuMAb Technology to research, make, have made, transfer physical possession of, but not to sell, lease, offer to sell or lease, or otherwise transfer title to, the Hybridoma Cell Lines.
Licensor grants a non-exclusive, worldwide, license, with the right to sublicense, under the Research Patent to conduct research.
For Research Antibodies License, Licensor grants an exclusive, worldwide license, without the right to sublicense, under the HuMAb Technology and the Licensor Technology to use the Research Antibodies for the sole purpose of determining the antigen with respect to which each Research Antibody was raised.
Licensor, who has incorporated Licensee for business opportunities outside of Licensors core business, irrevocably, perpetually and forever assigns and conveys Licensors entire right, title and interest in and to each of the following Assigned Assets
— Antibody Targeting Patents;
— Antibody Targeting Know-How;
— Anti-Mannose Receptor HuMAb Antibodies;
— the Investigational New Drug Application # 11,508 and related governmental filings, and the right to make any future or foreign related filing on –X-1307;
— all quantities of Biological Materials, including those in the possession or control of counterparties to Assigned Contracts;
— all clinical inventories of –X-1307 in the possession or control of Licensor as of the Effective Date; and
— the agreements that are Assigned Contracts.
Anti-Mannose Product shall mean any pharmaceutical composition or formulation incorporating an Anti-Mannose Receptor HuMAb Antibody.
HuMAb Mouse® shall mean any of Licensors immunizable transgenic mice containing unrearranged human immunoglobulin heavy and light chain transgenes, each inserted into mouse chromosomes, but excluding the Additional Mice. HuMAb Mice® shall mean more than one HuMAb Mouse.
The patents relate to Anti-FcyRI (CD64) antibodies.
— an antibody or fragment chemically attached or genetically fused to an antigen (including an antigen that is an antibody, or fragment thereof, that encodes an idiotype antigen), whereby the antibody, or fragment thereof, serves as a targeting means for delivering such antigen to an Antigen-Presenting Cell for the purpose of eliciting an immune response,
— an antibody or fragment chemically attached or genetically fused to a toxin or radionuclide, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such toxin or radionuclide to an Antigen-Presenting Cell for the purpose of decreasing, down-regulating or eliminating the activity of such Antigen-Presenting Cell,
— an antibody or fragment chemically attached or genetically fused to a cytokine, adjuvant, or other immuno-modulatory compound, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such compound to an Antigen-Presenting Cell for the purpose of modulating the activity of such Antigen-Presenting Cell, and
— an antibody, or fragment thereof, alone, whereby the antibody or fragment binds to a particular antigen on the surface of an Antigen-Presenting Cell and through such binding modulates the activity of such Antigen-Presenting Cell.
